相关实验视频

Updated: Jun 6, 2025

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

基于结构的药对ErbB4-激酶抑制的建模:用于发现乳腺癌小分子药物的系统计算方法

R Shaw¹, R Pratap²

¹Department of Chemistry, GLA University, Mathura, India.

SAR and QSAR in environmental research

|December 2, 2024

概括

研究人员发现了新的ErbB4激酶抑制剂,以对抗乳腺癌的耐药性. 当ErbB2抑制剂失败时,新型化合物显示为向治疗的前景.

科学领域:

在瘤学瘤学.
生物化学生物化学
药物发现药物发现药物发现

背景情况:

在20%的乳腺癌中,ErbB2激酶是主要点.
抗ErbB2的乳腺癌可能会依赖ErbB4.
向ErbB4提供了一种克服对ErbB2抑制剂耐药性的策略.

研究的目的:

确定ErbB4激酶的新型小分子抑制剂.
探索ErbB4作为耐药乳腺癌的治疗点.
为合理的药物设计提供基础,对抗ErbB4依赖性癌症.

主要方法:

使用ErbB4-lapatinib晶体结构进行基于结构的药模拟.
分子对接和MM-GBSA计算的结合亲和力.
切姆布尔数据库对潜在药物候选者的虚拟选.
用ADMET进行分析,以评估药理动力学和毒性特性.

主要成果:

确定了ErbB4抑制的关键药理特征.
选了Chembl数据库,以发现潜在的小分子抑制剂.
评估了11个入围候选药物的ADMET概况.
切姆布尔310724,切姆布尔521284和切姆布尔4168686表现出强大的ErbB4抑制,具有显著的结合自由能量 (分别为-99.84,-89.42和-86.06 kcal/mol).

结论:

这项研究成功地确定了有前途的新型ErbB4激酶抑制剂.
综合计算方法为设计向治疗提供了一个强大的框架.
这些发现为开发ErbB4依赖性乳腺癌的新疗法奠定了基础,特别是那些抗ErbB2抑制剂的乳腺癌.

关键词:

ADME ADME ADME ADME ADME ADME ADME ADME ADME ADME ADME ADME ADME ADME ADME ADME ADME ADME ADME ADME ADME ADME ADME ADME ADME ADME ADME ADME ADME ADME ADME ADME ADME ADME ADME ADME ADME 在这种情况下,ErbB4基因酶会产生ErbB4基因酶.在MM-GBSA中使用.分子对接的分子对接.制药器模型的制药模型.

更多相关视频

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...